

Pau Montesinos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3963960/publications.pdf>

Version: 2024-02-01

164
papers

7,564
citations

101384

36
h-index

60497

81
g-index

170
all docs

170
docs citations

170
times ranked

6635
citing authors

#	ARTICLE	IF	CITATIONS
1	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	13.9	796
2	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. <i>Blood</i> , 2020, 135, 2137-2145.	0.6	470
3	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 379-389.	3.3	396
4	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	0.6	393
5	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 984-997.	5.1	330
6	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. <i>Blood</i> , 2008, 111, 3395-3402.	0.6	303
7	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood</i> , 2009, 113, 775-783.	0.6	279
8	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010, 115, 5137-5146.	0.6	278
9	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 2020, 383, 2526-2537.	13.9	265
10	Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1595-1604.	0.8	227
11	Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. <i>Haematologica</i> , 2008, 93, 67-74.	1.7	188
12	International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1919-1926.	0.8	166
13	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , 2008, 112, 3130-3134.	0.6	154
14	How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. <i>Blood</i> , 2014, 123, 2777-2782.	0.6	130
15	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	2.5	114
16	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011, 117, 1799-1805.	0.6	112
17	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. <i>Haematologica</i> , 2009, 94, 1242-1249.	1.7	93
18	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010, 95, 424-431.	1.7	84

#	ARTICLE	IF	CITATIONS
19	Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. <i>Annals of Hematology</i> , 2018, 97, 1115-1153.	0.8	81
20	Cord Blood Transplantation from Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 86-94.	2.0	79
21	THE DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF THE PETHEMA GROUP AND REVIEW OF THE LITERATURE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011059.	0.5	77
22	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. <i>Leukemia</i> , 2015, 29, 1084-1091.	3.3	70
23	EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. <i>Bone Marrow Transplantation</i> , 2014, 49, 397-402.	1.3	63
24	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. <i>Leukemia</i> , 2021, 35, 62-74.	3.3	63
25	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011, 96, 1470-1477.	1.7	59
26	First-in-Human Phase I Study of ladademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 4260-4273.	0.8	59
27	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
28	Follow-up of patients with R/R FLT3-mutation positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	0.6	55
29	Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 730-740.	2.0	54
30	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	3.3	54
31	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 807-815.	1.1	53
32	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome negative adult lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1879-1894.	0.6	48
33	A prognostic model for survival after salvage treatment with FLAG-gemtuzumab-ogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 700-710.	1.2	44
34	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. <i>Blood</i> , 2018, 132, 2736-2736.	0.6	44
35	Treatment of young patients with Philadelphia chromosome positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2012, 159, 78-81.	1.2	43
36	A phase II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 763-772.	0.8	39

#	ARTICLE	IF	CITATIONS
37	Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. <i>Annals of Hematology</i> , 2014, 93, 299-307.	0.8	38
38	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncology</i> , 2016, 12, 293-302.	1.1	36
39	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 288-296.	1.7	36
40	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
41	Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study. <i>Blood</i> , 2016, 128, 4060-4060.	0.6	34
42	Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. <i>Bone Marrow Transplantation</i> , 2015, 50, 1465-1472.	1.3	33
43	Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1197-1206.	0.6	33
44	Myeloablative Cord Blood Transplantation in Adults with Acute Leukemia: Comparison of Two Different Transplant Platforms. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1725-1730.	2.0	31
45	Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. <i>Bone Marrow Transplantation</i> , 2014, 49, 1084-1088.	1.3	31
46	Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. <i>Bone Marrow Transplantation</i> , 2016, 51, 1307-1312.	1.3	31
47	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1463-1470.	2.0	31
48	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.	3.3	31
49	Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1589-1595.	2.0	30
50	Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 305-318.	0.2	30
51	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 40, 1-9.	0.4	29
52	Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, e294-e297.	1.7	29
53	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. <i>Blood Advances</i> , 2022, 6, 1278-1295.	2.5	29
54	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 92.	6.9	28

#	ARTICLE	IF	CITATIONS
55	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. <i>Annals of Hematology</i> , 2021, 100, 1181-1194.	0.8	27
56	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> , 2023, 141, 156-167.	0.6	27
57	Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies. <i>Pharmacogenomics Journal</i> , 2015, 15, 109-118.	0.9	26
58	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1989-2007.	0.8	26
59	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018, 132, 563-563.	0.6	26
60	Pharmacogenomics and the treatment of acute myeloid leukemia. <i>Pharmacogenomics</i> , 2016, 17, 1245-1272.	0.6	25
61	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 410-417.	2.0	24
62	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1387-1392.	2.0	24
63	Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. <i>Leukemia</i> , 2018, 32, 21-29.	3.3	24
64	<p>IDH1-mutated relapsed or refractory AML: current challenges and future prospects</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 19-32.	1.2	24
65	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 228-240.	1.2	24
66	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). <i>Leukemia and Lymphoma</i> , 2018, 59, 1113-1120.	0.6	23
67	Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. <i>Blood Reviews</i> , 2020, 44, 100675.	2.8	23
68	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 231-231.	0.6	23
69	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922.	3.3	23
70	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	23
71	Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. <i>Current Drug Metabolism</i> , 2018, 19, 55-74.	0.7	22
72	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	0.6	21

#	ARTICLE	IF	CITATIONS
73	Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 5395-5402.	2.5	21
74	Outcome of older (>=70 years) APL patients frontline treated with or without arsenic trioxide: an International Collaborative Study. <i>Leukemia</i> , 2020, 34, 2333-2341.	3.3	20
75	Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. <i>Blood</i> , 2019, 134, 14-14.	0.6	20
76	Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. <i>Cancer Research</i> , 2019, 79, CT184-CT184.	0.4	18
77	Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 146-154.	0.6	17
78	6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2021, 11, 163.	2.8	17
79	A Study of Incidence and Characteristics of Infections in 476 Patients from a Single Center Undergoing Autologous Blood Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2007, 86, 186-192.	0.7	16
80	T Cell-Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1060-1063.	2.0	16
81	Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 43-46.	0.8	16
82	Emerging strategies for the treatment of older patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 1583-1593.	0.8	16
83	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. <i>Annals of Hematology</i> , 2019, 98, 2081-2088.	0.8	16
84	Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 6-13.	2.0	16
85	A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2003-2014.	2.0	16
86	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 197-218.	1.3	15
87	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019, 76, 1-10.	0.4	15
88	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	0.6	15
89	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , 2021, 106, 3079-3089.	1.7	15
90	Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019, 102, 79-86.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. <i>Cancer</i> , 2019, 125, 2810-2817.	2.0	13
92	A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. <i>Cancer Medicine</i> , 2020, 9, 2317-2329.	1.3	13
93	Efficacy and safety of native versus pegylated <i>Escherichia coli</i> asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1634-1643.	0.6	13
94	Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. <i>Cancers</i> , 2022, 14, 1734.	1.7	13
95	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. <i>Blood Advances</i> , 2022, , .	2.5	13
96	Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. <i>BMC Cancer</i> , 2018, 18, 1100.	1.1	12
97	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 1146-1155.	0.6	12
98	Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021, 35, 1571-1585.	3.3	12
99	Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 735-746.	2.0	12
100	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	2.8	12
101	Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with <i>ex vivo</i> chemosensitivity. <i>British Journal of Haematology</i> , 2020, 189, 672-683.	1.2	11
102	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	2.8	11
103	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 659-668.	0.6	10
104	Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2016, 16, 1-2.	0.9	9
105	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. <i>Annals of Hematology</i> , 2019, 98, 2467-2483.	0.8	9
106	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-12.	0.6	9
107	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. <i>Blood</i> , 2015, 126, 1333-1333.	0.6	9
108	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. <i>Annals of Hematology</i> , 2017, 96, 1077-1084.	0.8	8

#	ARTICLE	IF	CITATIONS
109	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 436.	1.7	8
110	Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1199-1209.	0.5	8
111	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. <i>Scientific Reports</i> , 2020, 10, 5904.	1.6	8
112	Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 5677.	1.7	8
113	Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 512-516.	2.0	7
114	Significance of Increased Blastic-Appearing Cells in Bone Marrow Following Myeloablative Unrelated Cord Blood Transplantation in Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 388-395.	2.0	7
115	Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 614215.	1.3	7
116	A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1497-1508.	0.8	7
117	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. <i>Cancers</i> , 2021, 13, 2458.	1.7	7
118	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 30-30.	0.6	7
119	Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 1-18.	1.0	7
120	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
121	Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819.	1.5	6
122	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268.	1.2	6
123	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020, 104, 162-169.	1.1	6
124	Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives. <i>Pharmaceutics</i> , 2022, 14, 559.	2.0	6
125	QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML). <i>Annals of Oncology</i> , 2017, 28, v370.	0.6	5
126	Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. <i>Expert Review of Hematology</i> , 2020, 13, 1057-1065.	1.0	5

#	ARTICLE	IF	CITATIONS
127	Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e513-e522.	0.2	5
128	Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia. <i>Pharmaceutics</i> , 2022, 14, 878.	2.0	5
129	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
130	Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment. <i>Revista Iberoamericana De Micologia</i> , 2015, 32, 185-189.	0.4	4
131	Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S228-S229.	0.2	4
132	Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S231.	0.2	4
133	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	2.0	4
134	Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. <i>Cancers</i> , 2022, 14, 2342.	1.7	4
135	A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	4
136	DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019016.	0.5	3
137	Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain. <i>PharmacoEconomics - Open</i> , 2019, 3, 229-235.	0.9	3
138	Validation of a multivariable prediction model for postâ€­engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. <i>Mycoses</i> , 2019, 62, 418-427.	1.8	3
139	Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 83-87.	2.0	3
140	Updated results from DIAMOND-01 (CL124-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7023-7023.	0.8	3
141	Outcomes and prognostic factors of adults with refractory or relapsed Tâ€­cell acute lymphoblastic leukemia included in measurable residual diseaseâ€­oriented trials. <i>Hematological Oncology</i> , 2021, 39, 529-538.	0.8	3
142	A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 175.	2.8	3
143	Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. <i>Blood</i> , 2020, 136, 25-27.	0.6	3
144	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. <i>Leukemia Research</i> , 2022, 115, 106821.	0.4	3

#	ARTICLE	IF	CITATIONS
145	Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results. <i>Annals of Oncology</i> , 2019, 30, vi81.	0.6	2
146	Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. <i>Leukemia and Lymphoma</i> , 2019, 60, 2720-2732.	0.6	2
147	PF261 A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF SELINEXOR VERSUS PHYSICIAN'S CHOICE (PC) IN OLDER PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML). <i>HemaSphere</i> , 2019, 3, 82-83.	1.2	2
148	Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports. <i>Clinical Drug Investigation</i> , 2020, 40, 227-235.	1.1	2
149	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. <i>Leukemia and Lymphoma</i> , 2020, 61, 3287-3305.	0.6	2
150	Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-versus-host disease: Pharmacoeconomic assessment of hospital resource use in Spain. <i>Journal of Clinical Apheresis</i> , 2021, 36, 612-620.	0.7	2
151	Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs. <i>Medicina Clínica</i> , 2021, 156, 573-574.	0.3	2
152	Intensive (2+5) Or Semi-Intensive (FLUGA) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older. <i>Blood</i> , 2013, 122, 2687-2687.	0.6	2
153	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. <i>European Journal of Haematology</i> , 2021, 106, 724-733.	1.1	1
154	PF277 ALICE: AN AML STUDY WITH LSD1 INHIBITION IN COMBINATION WITH AZACITIDINE IN THE ELDERLY. <i>HemaSphere</i> , 2019, 3, 90.	1.2	1
155	Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine (ALICE Phase IIa Trial). <i>Blood</i> , 2020, 136, 22-22.	0.6	1
156	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. <i>Blood</i> , 2020, 136, 33-35.	0.6	1
157	Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 1921.	1.7	1
158	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 246-249.	0.6	0
159	Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study. <i>Leukemia Research</i> , 2020, 92, 106352.	0.4	0
160	Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. <i>Future Oncology</i> , 2021, 17, 215-227.	1.1	0
161	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 2727-2736.	0.6	0
162	Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 573-574.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Secondary AML. Hematologic Malignancies, 2021, , 71-101.	0.2	0
164	Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience. Blood, 2020, 136, 2-3.	0.6	0